A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA) [gefitinib] Versus Intravenous Docetaxel (TAXOTERE) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy

Trial Profile

A Randomized, Open-Label, Parallel Group, International, Multicenter, Phase III Study of Oral ZD1839 (IRESSA) [gefitinib] Versus Intravenous Docetaxel (TAXOTERE) in Patients With Locally Advanced or Metastatic Recurrent Non-Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Docetaxel; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms INTEREST
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 May 2011 Actual end date (October 2007) added as reported by ClinicalTrials.gov.
    • 12 May 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2011 Actual end date changed from 5 Sep 2007 to 1 Jun 2006 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top